Functional Validation of Doxorubicin-Induced Cardiotoxicity-Related Genes
Hananeh Fonoudi,Mariam Jouni,Romina B. Cejas,Tarek Magdy,Malorie Blancard,Ning Ge,Disheet A. Shah,Davi M. Lyra-Leite,Achal Neupane,Mennat Gharib,Zhengxin Jiang,Yadav Sapkota,Paul W. Burridge
DOI: https://doi.org/10.1016/j.jaccao.2023.11.008
IF: 8.422
2024-01-25
JACC CardioOncology
Abstract:Background Genome-wide association studies and candidate gene association studies have identified more than 180 genetic variants statistically associated with anthracycline-induced cardiotoxicity (AIC). However, the lack of functional validation has hindered the clinical translation of these findings. Objectives The aim of this study was to functionally validate all genes associated with AIC using human induced pluripotent stem cell–derived cardiomyocytes (hiPSC-CMs). Methods Through a systemic literature search, 80 genes containing variants significantly associated with AIC were identified. Additionally, 3 more genes with potential roles in AIC ( GSTM1 , CBR1 , and ERBB2 ) were included. Of these, 38 genes exhibited expression in human fetal heart, adult heart, and hiPSC-CMs. Using clustered regularly interspaced short palindromic repeats/Cas9–based genome editing, each of these 38 genes was systematically knocked out in control hiPSC-CMs, and the resulting doxorubicin-induced cardiotoxicity (DIC) phenotype was assessed using hiPSC-CMs. Subsequently, functional assays were conducted for each gene knockout on the basis of hypothesized mechanistic implications in DIC. Results Knockout of 26 genes increased the susceptibility of hiPSC-CMs to DIC. Notable genes included efflux transporters ( ABCC10 , ABCC2 , ABCB4 , ABCC5 , and ABCC9 ), well-established DIC-associated genes ( CBR1 , CBR3 , and RAC2 ), and genome-wide association study–discovered genes ( RARG and CELF4 ). Conversely, knockout of ATP2B1 , HNMT , POR , CYBA , WDR4 , and COL1A2 had no significant effect on the in vitro DIC phenotype of hiPSC-CMs. Furthermore, knockout of the uptake transporters ( SLC28A3 , SLC22A17 , and SLC28A1 ) demonstrated a protective effect against DIC. Conclusions The present findings establish a comprehensive platform for the functional validation of DIC-associated genes, providing insights for future studies in DIC variant associations and potential mechanistic targets for the development of cardioprotective drugs.
oncology,cardiac & cardiovascular systems